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Abstract
Background/objectives: Little is known about trends in risk factors and mortality for Aboriginal Australians with
heart failure (HF). This population-based study evaluated trends in prevalence of risk factors, 30-day and 1-year
all-cause mortality following first HF hospitalization among Aboriginal and non-Aboriginal Western Australians
in the decade 2000–2009.
Methods: Linked-health data were used to identify patients (20–84 years), with a first-ever HF hospitalization.
Trends in demographics, comorbidities, interventions and risk factors were evaluated. Logistic and Cox
regression models were fitted to test and compare trends over time in 30-day and 1-year mortality.
Results: Of 17,379 HF patients, 1,013 (5.8 %) were Aboriginal. Compared with 2000–2002, the prevalence (as history) of
myocardial infarction and hypertension increased more markedly in 2006–2009 in Aboriginal (versus non-Aboriginal)
patients, while diabetes and chronic kidney disease remained disproportionately higher in Aboriginal patients. Risk
factor trends, including the Charlson comorbidity index, increased over time in younger Aboriginal patients.
Risk-adjusted 30-day mortality did not change over the decade in either group. Risk-adjusted 1-year mortality
(in 30-day survivors) was non-significantly higher in Aboriginal patients in 2006–2008 compared with 2000–2002
(hazard ratio (HR) 1.44; 95 % CI 0.85-2.41; p-trend = 0.47) whereas it decreased in non-Aboriginal patients (HR 0.87;
95 % CI 0.78-0.97; p-trend = 0.01).
Conclusions: Between 2000 and 2009, the prevalence of HF antecedents increased and remained disproportionately
higher in Aboriginal (versus non-Aboriginal) HF patients. Risk-adjusted 1-year mortality did not improve in Aboriginal
patients over the period in contrast with non-Aboriginal patients. These findings highlight the need for better
prevention and post-HF care in Aboriginal Australians.
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Introduction
Indigenous minorities in affluent countries like Australia,
Canada, New Zealand and the United States have
considerably lower life expectancies compared with
the non-Indigenous populations [1]. Excess burden of
cardiovascular disease (CVD), including heart failure (HF),
is a principal contributor to these disparities [2–5]. This is
particularly pertinent in Australia, where Indigenous
(Aboriginal and Torres Strait Islander, hereafter Aboriginal)
people, colonised predominantly since the early 1800s, have
a life expectancy gap of 10 years [6] and a median age of
22 years compared with 37 years in other Australians.
Despite representing only 3 % (670,000 people) of the
Australian population, Aboriginal experience disadvantage
across virtually all health and of socio-economic indicators,
including education, employment and income [6].
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In Australia, CVD accounts for about a quarter of the
differential disease burden in the Aboriginal population
[7]. Prevalence of CVD is reported to be 1.3–2.5-fold
higher among Aboriginal people compared to non-
Aboriginal people [2, 3]. Many modifiable lifestyle risk
factors (smoking, physical inactivity, poor nutrition) and
CVD risk factors (diabetes, chronic kidney disease,
overweight/obesity, hypertension) are more common
in Aboriginal than non-Aboriginal populations [2, 3],
predisposing them to the development of CVD [8].
Heart failure (HF) is a common, morbid and costly
disease with poor prognosis [9]. It is a chronic, progres-
sive clinical syndrome that is characterised by underlying
structural or functional impairment of ventricular filling
or ejection of blood [10]. The cardinal manifestations
are fatigue and dyspnoea at rest or during physical activ-
ity, and often fluid retention, pulmonary congestion and/
or peripheral oedema [10].
HF is a sequelae of many CVD, including ischaemic
heart disease (IHD), hypertension, atrial fibrillation,
valvular heart disease and idiopathic cardiomyopathy,
often causing death [9]. Diabetes, obesity, chronic kidney
disease and rheumatic heart disease, which also dispro-
portionately affect Aboriginal populations [11, 12], are
other risk factors for HF [9].
Earlier longitudinal population-based studies from
Australia [13, 14] and other high socio-economic countries
[15–17] have reported sustained declines in short-term
and long-term mortality after initial hospitalization for HF,
corresponding to the era of better cardiovascular preven-
tion and evidence-based treatment for HF since the mid-
1990s. However, there is little literature pertaining to
Aboriginal populations. In a recent study, we reported that
for the period of 2000–2009, the incidence rate overall of
first hospitalization for HF was three to five times higher
for Aboriginal men and women than non-Aboriginal [18].
The prevalence and magnitude of risk factors for HF
drive its incidence. Thus, understanding trends in risk fac-
tor prevalence is important, with implications for preven-
tion and future service demand. Furthermore, differences
in mortality trends between Aboriginal and non-Aboriginal
patients are measures of quality of cardiovascular care and
secondary prevention of HF. However, there is little litera-
ture pertaining to trends in risk factors and mortality asso-
ciated with HF in the Australian Aboriginal population.
The purpose of this study was to examine and compare the
trends in antecedent risk factors, comorbidities and mortal-
ity in Aboriginal (versus non-Aboriginal) patients with first
hospitalization for HF between years 2000 and 2009.
Methodology
Setting
Western Australia (WA), the largest state of Australia,
has a land area twelve times that of United Kingdom,
and is the home of the third highest number of Aboriginal
Australians (13.2 %), of which an estimated 41 % live in re-
mote locations.
Data sources and study cohort
Since the 1970s, the WA Hospital Morbidity Data
Collections (HMDC) have recorded principal and second-
ary (up to 20) discharge diagnoses for all patients dis-
charged from all (149) public and private hospitals in WA
[19]. The HMDC is a core dataset of the WA Data Linkage
System and is routinely linked to other administrative data-
sets, e.g. the state death registry [19].
Using methods described previously [14, 18], we iden-
tified a population-based cohort using the HMDC com-
prising all WA residents, aged 20–84 years, who had their
first (index) HF inpatient hospitalization between January
2000 and December 2009. Patients were excluded if they
had any admission for HF in the previous 10 years from
their index admission. The International Classification of
Diseases, Ninth Revision (ICD9) and Tenth Revision
(ICD10) diagnostic codes (including 428× or I50×), were
used to code HF, as a principal discharge diagnosis, or a
secondary discharge diagnosis of HF [only where the prin-
cipal discharge diagnosis was a cardiovascular condition,
excluding acute myocardial infarction (AMI)].
The coding for HF as a principal diagnosis (n = 1,006)
in the WA HMDC has been validated against the Boston
diagnostic criteria [comprising categories of history
(dyspnoea), physical examination and chest radiography),
with a positive predictive value of more than 92 % for
‘definite’ HF [20]. Furthermore, discharge evidence-
based medications for HF and echocardiography reports
in the cohort were also examined in the validation
cohort [21].
Aboriginal status
Aboriginal status is routinely collected through self-
identification for patients admitted for hospital treat-
ment, although this is known to be under-recorded [22].
Since 2002, the coding of Aboriginal status in the
HMDC exceeds 90 % [23]. Since 2010, the National best
practice guidelines for collecting Indigenous status in
health datasets have been implemented to ensure
consistency and accurate recording of Indigenous status
to improve the reliability of the data [22]. Furthermore,
to reduce the impact of under-recording of Aboriginal
status, a patient was defined in our study as being
Aboriginal if at least 25 % of all hospital admissions
(since 1980) for that patient had been coded as Aboriginal
or Torres Strait Islander.
Antecedents of HF, comorbidities and procedures
Antecedents of HF and comorbidities (Table 1) were
identified using a fixed 5-year look-back or were
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Table 1 Characteristics of Aboriginal and non-Aboriginal patients with a ‘first-ever’ admission for heart failure between 2000–2009














Women, n (%) 136 (49.3) 153 (50.2) 224 (51.9) 0.78 2,102 (43.3) 2,003 (41.1) 2,726 (41.1) 0.03
Mean age ± SD (years) 53.8 ± 14.3 53.0 ± 13.9 54.9 ± 14.1 0.15 71.2 ± 10.8 71.0 ± 11.5 70.8 ± 11.8 0.03
Age groups, n (%)
• 20–34 years 36 (13.0) 33 (10.8) 35 (8.1) 46 (0.9) 54 (1.1) 80 (1.2)
• 35–49 years 68 (24.6) 85 (27.9) 119 (27.6) 0.36 190 (3.9) 240 (4.9) 335 (5.1) 0.01
• 50–64 years 99 (35.9) 117 (38.4) 159 (36.8) 839 (17.3) 866 (17.8) 1,253 (18.9)
• 65–84 years 73 (26.5) 70 (23.0) 119 (27.6) 3,780 (77.9) 3,712 (76.2) 4,971 (74.9)
Urban/Rural, n (%)
• Rural 217 (78.6) 230 (75.4) 325 (75.2) 0.54 1,111 (22.9) 1,099 (22.6) 1,521 (22.9) 0.89
• Urban 59 (21.4) 75 (24.6) 107 (24.8) 3,743 (77.1) 3,773 (77.4) 5,117 (77.1)
SEIFA –quintiles, n (%)
• 1st quintile (most disadvantaged) 148 (53.6) 150 (49.3) 194 (45.0) 0.04 228 (4.7) 193 (4.0) 269 (4.1)
• 2nd quintile 25 (9.1) 28 (9.2) 41 (9.5) 815 (16.8) 793 (16.3) 1,076 (16.2)
• 3rd quintile 72 (26.1) 79 (26.0) 124 (28.8) 1,768 (36.5) 1,762 (36.2) 2,498 (37.7) 0.001
• 4th quintile 27 (9.8) 32 (10.5) 64 (14.9) 929 (19.2) 1,049 (21.6) 1,448 (21.9)
• 5th quintile <5 (1.5) 15 (4.9) 8 (1.9) 1,100 (22.7) 1,068 (22.0) 1,333 (20.1)
With private medical insurance, n (%) <5 (1.1) 6 (2.0) 5 (1.2) 0.58 1,383 (28.5) 1,485 (30.5) 2,230 (33.6) <0.001
Length of stay, days ± SD 5.1 ± 5.9 5.3 ± 6.2 4.6 ± 4.9 0.12 7.3 ± 15.5 7.3 ± 9.5 6.6 ± 8.3 0.001
Comorbidities, n (%)a
All ischaemic heart diseaseb 117 (42.4) 134 (43.9) 182 (42.1) 0.88 2,516 (51.8) 2,368 (48.6) 3,004 (45.3) <0.001
Acute myocardial infarction 37 (13.4) 58 (19.0) 91 (21.1) 0.04 781 (16.3) 760 (15.6) 1,143 (17.2) 0.06
Unstable angina 35 (12.7) 37 (12.1) 60 (13.9) 0.77 846 (17.4) 761 (15.6) 733 (11.0) <0.001
Hypertension 164 (59.4) 192 (62.9) 312 (72.2) 0.001 2,575 (53.0) 2,568 (52.7) 3,791 (57.1) <0.001
Atrial fibrillation 59 (21.4) 50 (16.4) 102 (23.6) 0.06 2,001 (41.2) 2,108 (43.3) 2,951 (44.5) 0.01
Diabetes 164 (59.4) 191 (62.6) 268 (62.0) 0.70 1,407 (29.0) 1,459 (30.0) 2,158 (32.5) <0.001
Chronic kidney disease 96 (34.8) 114 (37.4) 179 (41.4) 0.19 944 (19.4) 941 (19.3) 1,495 (22.5) <0.001
Renal failure 38 (13.8) 42 (13.8) 53 (12.3) 0.78 143 (3.0) 129 (2.7) 191 (2.9) 0.65
COPD 83 (30.1) 89 (29.2) 119 (27.6) 0.75 1,200 (24.7) 1,021 (21.0) 1,234 (18.6) <0.001
Cerebrovascular disease 25 (9.1) 19 (6.2) 34 (7.9) 0.44 618 (12.7) 483 (9.9) 616 (9.3) <0.001
Rheumatic and valvular heart disease (rheumatic) 50 (18.1) 50 (16.4) 57 (13.2) 0.18 716 (14.8) 719 (14.8) 802 (12.1) <0.001
Interventions, n (%)
History/index PCI 9 (3.3) 31 (10.2) 33(7.6) 0.03 287 (5.9) 356 (7.3) 530 (8.0) <0.001
History/index CABG 10 (3.6) 16 (5.2) 20 (4.6) 0.64 291 (6.0) 285 (5.8) 298 (4.5) <0.001
History/index coronary angiography 96 (34.8) 144 (47.2) 186 (43.1) 0.01 1,909 (39.2) 2,166 (44.5) 3,213 (48.4) <0.001
Charlson index, n (%)
0 3 (1.1) 3 (1.0) 0 34 (0.7) 28 (0.6) 37 (0.6)
1–2 121 (43.8) 98 (32.1) 128 (29.6) 0.001 2,269 (46.7) 2,347 (48.2) 2,975 (44.8) 0.01
3–4 54 (19.6) 82 (26.9) 126 (29.2) 1,323 (27.3) 1,248 (25.6) 1,805 (27.2)
>4 98 (35.5) 122 (40.0) 178 (41.2) 1,229 (25.3) 1,249 (25.6) 1,822 (27.4)
Emergency admissions, n (%) 265 (96.0) 293 (96.1) 414 (95.8) 0.99 4,544 (93.6) 4,569 (93.8) 6,275 (94.5) 0.08
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concurrent with the index HF hospitalization. The
Charlson comorbidity index [24], a composite measure of
comorbidity burden, was calculated using the modified
Deyo algorithm [25]. Coronary angiography, percutan-
eous coronary intervention (PCI) or coronary artery
bypass grafting (CABG) were similarly identified.
Socio-economic status and geographical classification
Socio-economic Indices for Areas (SEIFA) [26] based on
residential postcodes and divided into quintiles (based
on pre-defined cut-points) were assigned to each patient,
as a proxy for socio-economic status. SEIFA was devel-
oped by the Australian Bureau of Statistics and ranks
areas in Australia according to relative socio-economic
advantage and disadvantage. The indexes are based on
information from the five-yearly Census, which indicate
the collective socio-economic characteristics living in a
particular area. The Index of Relative Socio-Economic
Disadvantage was used in our analysis [26].
The Accessibility/Remoteness Index of Australia
(ARIA) [27] classification and the greater Perth metro-
politan city definition [28] were used to dichotomise
place of residence into urban and rural.
Ethics approvals
Ethics approvals were obtained from the WA Aboriginal
Health Ethics Committee and the Human Research Ethics
Committees of the Western Australian Department of
Health and the University of Western Australia.
Statistical analysis
Three calendar periods of 2000–2002 (baseline period),
2003–2005, and 2006–2009 were used to describe and
test for trends. Trends in demographics, comorbidities,
interventions, and prevalence of risk factors were
assessed separately and compared between Aboriginal
and non-Aboriginal HF patients using ANOVA for age
and Cochrane-Armatage trend tests for categorical
variables.
For 30-day survival, we included all incident patients
admitted between January 2000 and November 2009,
with December 2009 used as the follow-up period for
the November 2009 cases. Survival to 1 year was re-
stricted to 30-day survivors from the 2000–2008 cohort.
Risk-adjusted multivariable logistic and Cox regression
models were fitted to test for trends in 30-day and
1-year mortality (in 30-day survivors) across the pe-
riods and the Aboriginal status and period interaction
was used to compare trends for Aboriginal and non-
Aboriginal patients. Risk factor adjustment included: age,
gender, period, Charlson comorbidity index, specific co-
morbidities including hypertension, atrial fibrillation,
rheumatic/valvular heart disease, diabetes, chronic kidney
disease/renal failure, AMI, other IHD, cerebrovascu-
lar disease, and history of PCI/CABG. Additionally,
PCI and CABG during index admission were mod-
elled for 1-year mortality in 30-day survivors only.
Statistical analyses were undertaken with SAS 9.3
and STATA 12.0 for Windows.
Results
Of 17,379 patients with first HF hospitalization, 1,013
(5.8 %) were Aboriginal. Compared to non-Aboriginal
HF, Aboriginal patients had a higher proportion of
women and were younger (mean age 54 years vs
71 years non-Aboriginal) (Table 1) with mean age
remaining 16–18 years lower at first HF hospitalization
over the period. HF presentations by rural Aboriginal
patients declined whilst urban presentations increased,
but both were not-significant. There was no change
in non-Aboriginal patients. Although about half the
Aboriginal patients were from areas in the lowest
quintile of social disadvantage, the proportion of
Aboriginal patients in the lowest (1st) quintile fell
significantly (8.6 %) overall (p = 0.04). The proportion
with private medical insurance increased significantly
in non-Aboriginal patients but no change was evident in
Aboriginal patients where less than 2 % had private
health insurance. A declining trend in length of stay
during the index HF hospitalisation was seen in both
populations, although not statistically significant in the
Aboriginal group.
Table 1 Characteristics of Aboriginal and non-Aboriginal patients with a ‘first-ever’ admission for heart failure between 2000–2009
(Continued)
Crude cumulative mortality
30-day case fatalityc 13 (4.7) 16 (5.3) 19 (4.6) 0.91 332 (6.8) 350 (7.2) 414 (6.4) 0.20
1-year mortalityd 38 (13.8) 49 (16.1) 55 (17.5) 0.46 1,059 (21.8) 1,018 (20.9) 974 (19.7) 0.04
Continuous variables expressed as mean ± standard deviation (SD). Categorical variables expressed as count (n) and proportion (%)
aPatients could have multiple comorbidities. COPD = chronic obstructive pulmonary disease
bAll ischaemic heart disease includes acute myocardial infarction
History/index PCI percutaneous coronary interventions as history or concurrent with index HF admission
History/index CABG coronary artery bypass graft as history or concurrent with index HF admission
cCases stopped at 30 November 2009 to all 30-day follow-up in December 2009
dCases stopped at 31 Dec 2008 to allow 1-year follow-up in 2009 for the 2008 cases
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Trends in risk factors and HF antecedents
The prevalence of IHD showed a small but significant
decline in non-Aboriginal patients [51.8 % (2000–2003),
45.3 % (2006–2009) p < 0.001] whereas IHD remained
stable in Aboriginal patients (p = 0.88) (Table 1). The
prevalence of AMI and hypertension, two key anteced-
ents of HF, increased more markedly in Aboriginal than
non-Aboriginal patients over the 10-years (Fig. 1).
Specifically, the upward trend for AMI was greater in
Aboriginal (from 13.4 % to 21.1 %, p = 0.04) than non-
Aboriginal patients (from 16.3 % to 17.2 %, p = 0.06). In
all time periods, the prevalence of diabetes and chronic
kidney disease was double in Aboriginal patients and
increased in both populations over the study period,
although not significantly so in Aboriginal patients.
Similarly, the prevalence of renal failure was 4-fold
higher in Aboriginal patients throughout. Trends in un-
stable angina, cerebrovascular disease and chronic ob-
structive pulmonary disease showed significant declines
in non-Aboriginal patients only (Table 1). Prevalence of
rheumatic/valvular heart disease showed a decline in
both subpopulations (though not significantly in Aboriginal
patients), suggesting some success in rheumatic heart dis-
ease prevention.
In terms of composite comorbidity burden, the change
in distribution of the Charlson index over the periods
was significantly different in Aboriginal and non-
Aboriginal patients (three-way interaction between
Charlson index, Aboriginality and period p = 0.01). The
proportion with a Charlson index score ≥3 increased
over time in Aboriginal patients, but was relatively stable
in non-Aboriginal patients, with no clinically important
trend. Uptake of PCI and coronary angiography in-
creased significantly in both populations, peaking during
2003–2005 in Aboriginal patients. Acute emergency
presentations for HF occurred in the vast majority
(>94 %), with no significant change over the period.
Trends in mortality
Crude 30-day mortality did not change over the study
period in either population (Table 1). Risk-adjusted 30-
day mortality was also not significantly different between
the base and last time periods in both Aboriginal (OR
0.98, 95 % CI 0.46-2.08, p = 0.98) and non-Aboriginal
patients (OR 0.93, 95 % CI 0.80-1.09, p = 0.38).
Crude 1-year mortality showed a non-significant increase
over the period in Aboriginal patients (p-trend = 0.46), but
decreased slightly from 21.8 % to 19.7 % in non-Aboriginal
patients (p-trend = 0.04). Risk-adjusted 1-year mortality
(Table 2) was non-significantly higher (HR 1.44 95 % CI
0.85-2.41) in Aboriginal patients in 2006–2008 com-
pared with 2000–2002 (p-trend = 0.47), whereas it
declined significantly (HR 0.87 95 % CI 0.78-0.97) in
non-Aboriginal patients (p-trend =0.01). Independent
predictors associated with increased hazards of 1-year
adjusted mortality have been reported previously [18]
and listed in Table 2. Increasing age, rural residence,
lack of private medical insurance, emergency admission,
history of CKD/renal failure, AMI and COPD were
other independent predictors in non-Aboriginal patients
and the whole cohort (data not shown). Notably, the
weighted Charlson comorbidity index was the strongest
independent predictor of increased hazard (by 26 % for
an increase in one unit) in Aboriginal patients.
Discussion
Assessment of modifiable risk factors and outcome
trends are important for evaluating key drivers and pat-
terns of disease in the populations and for informing
health policy. Over the decade (2000–2009), we observed
Fig. 1 Trends in prevalence of specific risk factors for heart failure in Aboriginal and non-Aboriginal patients, Western Australia 2000–2009
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that key conditions associated with the development of
HF increased in the Aboriginal HF patients. Recurrent
AMI, hypertension and diabetes are some of the most
important risk factors for developing HF [29, 30]. Over
the study period, the marked increase in trends of AMI
and hypertension in Aboriginal patients and the dispro-
portionate prevalence of diabetes and chronic kidney
disease highlight their significantly elevated burden of
vascular risk. Of note is the declining trend in RHD
among Aboriginal HF patients. Apart from these spe-
cific diseases, Aboriginal people with HF also have a
substantial burden of other serious conditions (Charlson
score ≥3) which increased over the study period. With re-
spect to outcomes, our study indicates that despite ad-
vances in medical therapies, the 1-year adjusted survival
(in 30-day survivors) following first HF hospitalization did
not improve in Aboriginal patients over the 10-year
period, contrasting with the significant improvement seen
in non-Aboriginal patients and previously reported for the
Western Australian population [13].
Aboriginal patients are however presenting at an older
age for first HF hospitalization, with less presentations
in those aged 20–34 years, suggesting some success in
primary prevention programs. There was also a signifi-
cant reduction the proportion of Aboriginal patient in
the most disadvantaged quintile of area-level indices.
While IHD is still a key contributor to HF, coronary
angiography uptake has increased and was similar in
both populations. These results indicate that any socio-
economic and health service access gains made by the
Table 2 Stratified multivariable Cox regression models for 1-year mortality in 30-day survivors, Aboriginal and non-Aboriginal patients
Non-Aboriginal patients Aboriginal patients
Hazard ratio (HR) 95 % CI p-value Hazard ratio (HR) 95 % CI p-value
Age 1.04 1.03–1.05 <0.001 1.00 0.99–1.02 0.62
Female sex 0.89 0.81–0.97 0.010 0.97 0.64–1.45 0.87
2000–2002 1.00 1.00
2003–2005 0.94 0.85–1.05 0.272 1.21 0.71–2.07 0.479
2006–2008 0.87 0.78–0.97 0.010 1.44 0.85–2.41 0.149
Metropolitan residence 1.00 1.00
Rural residence 1.16 1.03–1.31 0.012 0.75 0.41–1.38 0.354
No private medical insurance 1.15 1.04–1.27 0.007 0.88 0.12–6.62 0.904
SEIFA - 1st quintile (least disadvantaged) 1.00 1.00
2nd quintile 0.97 0.76–1.24 0.793 0.69 0.31–1.54 0.363
3rd quintile 0.98 0.77–1.24 0.844 0.37 0.18–0.75 0.006
4th quintile 1.03 0.80–1.32 0.837 0.70 0.32–1.53 0.372
5th quintile 1.07 0.83–1.38 0.606 0.84 0.24–2.95 0.787
Emergency admission 1.54 1.18–2.00 0.001 1.61 0.38–6.75 0.515
Comorbidities
Hypertension 0.83 0.75–0.91 <0.001 0.41 0.25–0.68 <0.001
Atrial fibrillation 0.96 0.87–1.04 0.313 0.96 0.57–1.62 0.885
Rheumatic heart disease 1.28 1.00–1.65 0.051 0.31 0.07–1.35 0.119
Diabetesa 0.72 0.64–0.80 <0.001 1.00 0.56–1.80 0.999
Chronic kidney diseasea 1.24 1.11–1.39 <0.001 0.64 0.37–1.11 0.116
Renal failurea 1.36 1.10–1.69 0.005 1.54 0.85–2.80 0.157
Acute myocardial infarction 1.32 1.17–1.48 <0.001 1.55 0.91–2.64 0.109
Ischaemic heart disease 0.87 0.79–0.96 0.006 1.08 0.68–1.71 0.754
Cerebrovascular disease 1.01 0.89–1.15 0.848 1.21 0.63–2.35 0.567
Charlson comorbidity index 1.20 1.18–1.23 <0.001 1.26 1.14–1.39 <0.001
All valvular heart disease 1.02 0.92–1.12 0.745 1.10 0.65–1.87 0.719
COPD 1.11 1.00–1.22 0.047 1.01 0.66–1.54 0.962
PCI (history or 1st admission) 0.66 0.54–0.80 0.000 0.17 0.04–0.73 0.017
CABG (history or 1st admission) 0.65 0.51–0.83 0.001 0.37 0.09–1.60 0.186
aAlso included in computation of the Charlson comorbidity index
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Aboriginal population (as reflected by access to angiog-
raphy and RHD prevalence) is not yet reflected in this
cohort and that evidence of progress towards reducing
HF antecedents and outcomes may only be observed in
the future.
In aggregate terms, trends in CVD risk factors for HF
point to an increased risk of HF for the Aboriginal
group, despite being considerably younger. The substan-
tial social inequities between Aboriginal compared with
non-Aboriginal patients (with SEIFA and private medical
insurance status as proxies) play a big role in the burden
of CVD generally, despite the small but significant de-
cline in the lowest quintile of socio-economic disadvan-
tage in Aboriginal patients over the study period. The
reasons for the adverse trends in precursors to HF may
also include suboptimal secondary prevention of HF an-
tecedents and poorer post-discharge care and follow-up.
The widening of the gap in one-year outcomes re-
ported in the current study reflects challenges in
secondary prevention of HF in Aboriginal patients.
Implementation and delivery of guideline-based HF care
for rural Aboriginal patients (where the majority reside)
is complex [31], challenged by socio-economic, language
and cultural factors, poor access to specialist services,
poorer access to primary health care [32] and lower par-
ticipation in post-discharge programs [31]. Despite the
higher prevalence of HF in rural areas, lower rates of
prescription of evidence-based therapy (e.g. ACE inhibi-
tor drugs), echocardiography for diagnosis and specialist
referral have been reported in rural (vs metropolitan
areas) [33]. Indeed, a recent study in 3 Northern Territory
communities found that 65 % of patients identified with
heart failure were previously undiagnosed [34]. Further-
more, difficulties with recruitment and retention of ad-
equately trained health professionals in rural/remote areas
render current integration and continuity of care for
Aboriginal patients (many with multimorbidity), woefully
inadequate [35, 36].
HF usually reflects the end stage of underlying heart
conditions, so that HF prevention includes primary pre-
vention of these conditions. Our results suggest gains in
primary prevention of CVD in Aboriginal people are lag-
ging, with further management of key antecedents of HF
being inadequate. Data from our previous study [18]
showed widening (adjusted) disparities after the first
month post-discharge for Aboriginal patients. Com-
pounding this picture of health inequalities, Aboriginal
patients who survive a major coronary event are also less
likely (than non-Aboriginal patients) to attend a cardiac
rehabilitation programs with location of such services in
predominantly urban and major regional centres [37],
reflecting inequalities in health services access in the
community. Social, policy and systems change are
needed across multiple sectors to reduce the Aboriginal
social disadvantage contributing to adverse risk factor
trends (of antecedents) and barriers to accessing health
services. There is an urgent need for environments that
facilitate healthy choices to reduce risk factors contribut-
ing to premature HF. Furthermore, primary health care
(as the cornerstone of health services system) need to be
strengthened and access to cardiac rehabilitation im-
proved for Aboriginal people in WA.
The risk factor trends suggest potential differences in
epidemiological transition of HF between both popula-
tions, at least for rheumatic heart disease, for which
Aboriginal people still have very high rates [38]. The
declining trend in RHD may be due to progress from co-
ordinated programs targeted at improved detection,
monitoring, management and prophylaxis of acute
rheumatic fever/rheumatic heart disease in the Aboriginal
community [38].
Although this study is specific to Aboriginal Australians
in Western Australia, Aboriginal Australians share similar
clinical, socio-demographic and historical characteristics
with other Indigenous populations around the world [3].
Furthermore, epidemiological findings from one region or
a particular ethnic group are likely to be relevant to an-
other region or ethnic group [39].
Unfavourable trends in some key risk factors for
cardiovascular diseases were similarly reported to under-
lie the slowing of the decline in IHD deaths among
Aboriginal Australians in the younger age groups [40].
Separately, we also observed a two-fold adjusted hazard
of 1-year mortality in 30-day survivors in younger
Aboriginal Australians (less than 55 years) following in-
cident HF hospitalization [18]. These are consistent with
the findings from a Canadian study, which reported that
the relative risk of dying from CVD for First Nations
people (compared to non-Aboriginal cohort) was highest
in the younger age groups (25–34 years) [41]. Other
studies from Canada showed a 2.5-fold higher preva-
lence of CVD in Aboriginal people (vs non-Aboriginal
people of European descent) [3], similar IHD mortality
rates among Aboriginal and Canadian males, but 61 %
higher IHD mortality among Aboriginal women com-
pared with Canadian women [39]. A more recent
study from Alberta also observed 18 % to 39 % higher
adjusted mortality at 1-year and 5 years, respectively,
in Aboriginal (vs non-Aboriginal) patients following index
HF hospitalization [8].
The strengths of this study lie in the quality and near
complete ascertainment of the short-term and 1-year
mortality following the index hospitalisation for HF
using the WA HMDC [19] and the validation of a prin-
cipal diagnosis of HF [20]. However, we do not have
medication records, echocardiography findings and clin-
ical data recorded within administrative data. Further-
more, there are unrecorded factors (such as smoking,
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diet and alcohol use) affecting Aboriginal health and en-
vironmental factors which could adversely affect health
outcomes. The use of an area-based measure (SEIFA), as
an indicator for social deprivation, could give rise to po-
tential misclassification at an individual level.
Conclusions
This population-based cohort study showed widening
disparities between Aboriginal and non-Aboriginal pa-
tients with HF in both key individual risk factors and
composite comorbidity index. The mortality trends high-
light that gains in secondary prevention in the main-
stream population have not been achieved in the
younger, Aboriginal population. This disparity warrants
urgent policy attention particularly around prioritising
better prevention of heart disease, enhanced surveillance
for heart disease and management of antecedents in pri-
mary care. Since up to 80 % of premature cardiovascular
disease is preventable, it is possible to substantially re-
duce this disproportionate burden of CVD in Aboriginal
Australians through addressing the underlying material,
social and environmental factors associated with disad-
vantage. These disadvantages are a significant barrier to
the effectiveness of medical interventions [42], so up-
stream interventions to reduce risk factors will also
support efforts directed at improving treatment of HF.
Since primary care plays a central role in mitigating
CVD in the population, strenuous efforts to strengthen
primary health care and improve access to cardiac rehabili-
tation, particularly outside of metropolitan areas, are
needed to complement population prevention measures.
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